Currently out of the existing stock ratings of Jonathan Demchick, 12 are a HOLD (63.16%), 4 are a BUY (21.05%), 3 are a SELL (15.79%).

Jonathan Demchick

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Demchick, currently employed carries an average stock price target met ratio of 85.71% that have a potential upside of 8.87% achieved within 279 days. Previously, Jonathan Demchick worked at MORGAN STANLEY.

Jonathan Demchick’s has documented 34 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on NUVA, NuVasive at 04-Aug-2023.

Wall Street Analyst Jonathan Demchick

Analyst best performing recommendations are on GMED (GLOBUS MEDICAL).
The best stock recommendation documented was for NUVA (NUVASIVE) at 5/31/2023. The price target of $40 was fulfilled within 12 days with a profit of $1.84 (4.82%) receiving and performance score of 4.02.

Average potential price target upside

GMED Globus Medical IART Integra LifeSciences Holdings NUVA NuVasive AVNS Avanos Medical

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

14 days ago
(07-Nov-2024)

2/3 (66.67%)

$10.44 (17.24%)

115

Buy

$88

$6.9 (8.51%)

$78

15 days ago
(06-Nov-2024)

8/9 (88.89%)

$7.85 (9.79%)

266

Buy

$100

$18.9 (23.30%)

$75

15 days ago
(06-Nov-2024)

8/12 (66.67%)

$19.85 (24.77%)

268

Buy

$100

$18.9 (23.30%)

$80

15 days ago
(06-Nov-2024)

14/19 (73.68%)

$19.85 (24.77%)

224

Buy

$92

$10.9 (13.44%)

$70

15 days ago
(06-Nov-2024)

7/8 (87.5%)

$11.85 (14.78%)

127

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Jonathan Demchick?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?